NCT06758700 Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
| NCT ID | NCT06758700 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Condition | Extensive-stage Small Cell Lung Cancer (ES-SCLC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-02-07 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 15 participants in total. It began in 2025-02-07 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Eligibility Criteria
Inclusion Criteria: 1. extensive stage small cell lung cancer 2. Progression after receiving at least one chemotherapy drug treatment in the past; 3. ECOG score 0-1 4. c-Myc-driven 5. Expected survival period ≥3 months 6. Age: 18-75 years old; 7. The informed consent form complies with the ICH-GCP principles. Exclusion Criteria: 1. No measurable lesions 2. Other severe and persistent diseases or organ system dysfunction; 3. Women planning pregnancy or men planning family planning; 4. Women who are pregnant or breastfeeding; 5. Those who cannot follow the research protocol provided by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06758700 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Extensive-stage Small Cell Lung Cancer (ES-SCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06758700 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06758700 currently recruiting?
Yes, NCT06758700 is actively recruiting participants. Contact the research team at wangjiale200008@163.com for enrollment information.
Where is the NCT06758700 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06758700 clinical trial?
NCT06758700 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.